These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20008249)

  • 1. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
    Santos FP; Verstovsek S
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Benson KL; Mesa RA
    Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
    Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 inhibitors and their impact in myeloproliferative neoplasms.
    Geyer HL; Tibes R; Mesa RA
    Hematology; 2012 Apr; 17 Suppl 1():S129-32. PubMed ID: 22507800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New generation small-molecule inhibitors in myeloproliferative neoplasms.
    Passamonti F; Maffioli M; Caramazza D
    Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthroughs in myeloproliferative neoplasms.
    Santos FP; Verstovsek S
    Hematology; 2012 Apr; 17 Suppl 1():S55-8. PubMed ID: 22507780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 inhibitors: what's the true therapeutic potential?
    Santos FP; Verstovsek S
    Blood Rev; 2011 Mar; 25(2):53-63. PubMed ID: 21095048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
    Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
    J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.
    Wadleigh M; Tefferi A
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):557-63. PubMed ID: 20966892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 inhibitors: are they the solution?
    Santos FP; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes R; Mesa RA
    Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
    Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
    Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.